AB0486 ONE-YEAR DIRECT COSTS OF BIOLOGICAL THERAPY IN ANKYLOSING SPONDYLITIS AND ITS PREDICTIVE FACTORS: DATA FROM THE MOROCCAN RBSMR REGISTRY

Background: NA Objectives: To estimate the annual direct costs of biological therapies in Spondyloarthropathies (SpA) and to establish possible factors associated with those costs. Methods: The main data source was the Moroccan registry of biological therapies in rheumatic diseases (RBSMR). We included SpA patients with available 1-year data. Variables related to socioeconomic status, disease and biological therapy were collected. Differences in costs across groups were tested by Mann–Whitney and Kruskal–Wallis tests. Correlations analysis was performed in search of factors associated with high costs. Results: We included 89 SpA patients. The mean age was 40.6± 13.6 years, with male predominance 68.9 %. Patients received one of the following therapies: TNF-blockers (n =79), Biosimilar of TNF-blockers (n =8) and Il17-blockers (n =2). Median one-year biologic costs per patient were 9 569, 39 €. The total annual of biotherapies in AS patients was 851 675, 98 €. The costs are presented in Euro using an exchange rate of (1 Moroccan Dirham = 0.091Euro). TNF-blockers constituted 95 % of the total annual budget. Biosimilar of TNF-blockers and Il17-blockers represented 3 % and 2 % of this overall budget, respectively. Although the costs were not significantly different in terms of gender or level of study, the insurance type significantly affected the cost estimation. No correlation was found between the annual direct costs of biotherapies and body mass index nor with BASFI or BASDAI. Conclusion: In Morocco, a developing country, the annual direct costs of biological therapies are high in AS patients. Our results may contribute to the development of strategies for better governance of these costs. Disclosure of Interests: None declared.